DJIA 18,041.54 -190.48 -1.04%
NASDAQ 5,032.75 0.00 0.00%
S&P 500 2,104.20 -21.86 -1.03%
market minute promo

Novartis (NYSE: NVS)

101.81 0.00 (0.00%)

REAL-TIME: Last trade at

Extended Hours: $102.69 $0.88 (0.86%)
Quote as of (NYSE)



company name or ticker

Recent Quotes

NVS $101.81 0.00%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.00
Previous Close $101.81
Daily Range $0.00 - $0.00
52-Week Range $84.17 - $105.82
Market Cap $244.2B
P/E Ratio 27.52
Dividend (Yield) $2.67 (2.2%)
Ex-Dividend Date
Dividend Pay Date
03/02/15
04/20/15
Volume 300
Average Daily Volume 1,158,025
Current FY EPS $5.21

Sector

Healthcare

Industry

Drug Makers

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website: http://www.novartis.com/

News & Commentary Rss Feed

Billionaire George Soros Just Sold These 3 Stocks: Should You?

The Soros Fund Management sold Kite Pharma, Valeant Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. in the first quarter. Should you follow in its footsteps?

Will Competition Cause Teva Pharmaceutical Industries ltd. To Tumble?

The FDA has approved Novartis' biosimilar to Teva Pharmaceuticals' Copaxone.

Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog

Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog

Novartis Reports Two Positive US Phase III Programs in COPD for QVA149, NVA237

Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 21, 2015

Biosimilars Vs Generics: History Does Not Repeat, It Rhymes

Could This Be Healthcare's $158 Billion Black Swan Event?

This unlikely event is becoming increasingly more likely -- and the impact would be enormous.

2 Stocks With Jaw-Dropping Growth Potential

These 2 companies are high-risk investments, but they nonetheless have the potential to become pivotal players in the rapidly expanding field of immuno-oncology. Here's why.

Baxter Takes The Acquisition Route To Grow In The Oncology Segment

Teva Pharmaceutical Industries Limited (TEVA) Ex-Dividend Date Scheduled for May 15, 2015

See More NVS News...

NVS's Top Competitors

NVS $101.81 (0.00%)
Current stock: NVS
JNJ $100.82 (0.00%)
Current stock: JNJ
MRK $58.97 (0.00%)
Current stock: MRK
GSK $43.84 (0.00%)
Current stock: GSK